Earnings Feed
Start Free
Apellis Pharmaceuticals, Inc.·4

Jan 21, 4:16 PM ET

Deschatelets Pascal 4

Research Summary

AI-generated summary

Updated

Apellis (APLS) CSO Pascal Deschatelets Sells 909 Shares

What Happened

  • Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals (APLS), sold 909 shares on January 20, 2026 at $19.79 per share, generating proceeds of $17,992. The filing indicates the sale was to cover tax withholding on Restricted Stock Units released January 16, 2026.

Key Details

  • Transaction date and price: 2026-01-20, 909 shares at $19.79 each.
  • Total proceeds: $17,992.
  • Shares owned after transaction: Not specified in the provided filing.
  • Transaction code: S (sale); footnote F1: sale made to cover tax withholding on RSUs released 1/16/2026.
  • Filing date: 2026-01-21 (appears timely based on the reported transaction date).

Context

  • Sales to cover tax withholding on RSU vesting are routine and typically administrative (not a direct signal of confidence or lack thereof in the company). This was not an option exercise or a purchase; it was a disposal to satisfy taxes.